Wills Hughes-Wilson is Vice President Global Public Policy & Government Relations Sobi (Swedish Orphan Biovitrum) and member of the Global Management Team. She joined Sobi in February 2012.
Hughes-Wilson is responsible for external liaison with policy and government stakeholders working to support the availability of treatments for rare diseases on behalf of Sobi; and for supporting the development of sustainable healthcare systems for rare disease diagnosis, treatment and care.
She has been actively involved in DIA since 2001, organising Tutorials at several EuroMeetings, co-Chairing the newly established HTA Forum in 2009 and 2010, as well as being a EuroMeeting Theme Leader in 2009, 2010 & 2011. She has been an ACE member since 2010. She has also participated in workshops with the DIA leadership focussed on examining the future role and offering of the Association, notably in the field of membership services and DIA’s future engagement in the HTA and Health Outcomes space.
Hughes-Wilson is a member of the European Commission’s newly established EU Committee of Experts on Rare Diseases (EUCERD), the standing committee responsible for advising the European Commission on all aspects of implementing effective rare disease policies across Europe. This includes key aspects around reimbursed access to orphan drugs.
Hughes-Wilson is also Chair of the joint European Industry Task Force on Orphan Drugs & Rare Diseases.
Prior to joining Sobi, Hughes-Wilson was the head of Health- & Market Access Policy at Genzyme EMEA for more than 6 years. She has led the Emerging Biopharmaceutical Enterprises (EBE), a specialised group of the European Federation of Pharmaceutical Industries & Associations (EFPIA), representing the interests of biotechnology companies in Europe, as well as holding key positions in the animal health / veterinary medicines industry and Ernst & Young Consulting.
Hughes-Wilson is an Honours graduate in Law.